{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:47:17Z","timestamp":1793213237044,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00520-018-4087-3","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T22:44:37Z","timestamp":1518475477000},"page":"2471-2477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3701-5663","authenticated-orcid":false,"given":"Napa","family":"Parinyanitikul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walailuk","family":"Tanpipattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaya","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanapoom","family":"Rattananupong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poranee","family":"Laoitthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyada","family":"Sithidetphaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suebpong","family":"Thanasanvimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"issue":"12","key":"4087_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","volume":"12","author":"EA Eisenhauer","year":"1994","unstructured":"Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J Clin Oncol 12(12):2654\u20132666. \n                    https:\/\/doi.org\/10.1200\/JCO.1994.12.12.2654","journal-title":"J Clin Oncol"},{"issue":"1","key":"4087_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"344","author":"WP McGuire","year":"1996","unstructured":"McGuire WP et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patient with stage III and IV ovarian cancer. N Engl J Med 344(1):1\u20136","journal-title":"N Engl J Med"},{"issue":"17","key":"4087_CR3","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1200\/JCO.2002.12.112","volume":"20","author":"P Kosmidis","year":"2002","unstructured":"Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20(17):3578\u20133585. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.12.112","journal-title":"J Clin Oncol"},{"issue":"12","key":"4087_CR4","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.1997.15.12.3517","volume":"15","author":"M Markman","year":"1997","unstructured":"Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1997) Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reaction. J Clin Oncol 15(12):3517. \n                    https:\/\/doi.org\/10.1200\/JCO.1997.15.12.3517","journal-title":"J Clin Oncol"},{"issue":"6","key":"4087_CR5","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.1996.14.6.1895","volume":"14","author":"MA Bookman","year":"1996","unstructured":"Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF (1996) Carboplatin and paclitaxel in ovarian cancer: a phase I study of Gynecologic Oncology Group. J Clin Oncol 14(6):1895\u20131902. \n                    https:\/\/doi.org\/10.1200\/JCO.1996.14.6.1895","journal-title":"J Clin Oncol"},{"issue":"2","key":"4087_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1006\/gyno.1998.4993","volume":"69","author":"JP Micha","year":"1998","unstructured":"Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV (1998) Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69(2):122\u2013124. \n                    https:\/\/doi.org\/10.1006\/gyno.1998.4993","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4087_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reaction: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102\u2013105. \n                    https:\/\/doi.org\/10.1200\/JCO.2000.18.1.102","journal-title":"J Clin Oncol"},{"issue":"2","key":"4087_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1010618632738","volume":"19","author":"L Zuylen Van","year":"2001","unstructured":"Van Zuylen L et al (2001) Role of formulation vehicles in taxanepharmacology. Invest N drugs 19(2):125\u2013141. \n                    https:\/\/doi.org\/10.1023\/A:1010618632738","journal-title":"Invest N drugs"},{"key":"4087_CR9","first-page":"268","volume":"4","author":"M Lassus","year":"1985","unstructured":"Lassus M et al (1985) Allergic reaction associatied with cremophor E containing antineoplastic. Proc Am Clin Oncol 4:268","journal-title":"Proc Am Clin Oncol"},{"issue":"5","key":"4087_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00001813-200006000-00003","volume":"11","author":"L Zuylen Van","year":"2000","unstructured":"Van Zuylen L et al (2000) Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 11(5):331\u2013337. \n                    https:\/\/doi.org\/10.1097\/00001813-200006000-00003","journal-title":"Anti-Cancer Drugs"},{"key":"4087_CR11","first-page":"712","volume":"1","author":"J Szebeni","year":"2001","unstructured":"Szebeni J et al (2001) Formation of complement activating particle in aqueous solution of Taxol: possible role in hypersensitivity reaction. Int Immuno Pharmacol 1:712\u2013735","journal-title":"Int Immuno Pharmacol"},{"issue":"7","key":"4087_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, van Echo DA, von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263\u20131268. \n                    https:\/\/doi.org\/10.1200\/JCO.1990.8.7.1263","journal-title":"J Clin Oncol"},{"issue":"1","key":"4087_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-004-0924-9","volume":"56","author":"T Sendo","year":"2005","unstructured":"Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, Nakano H, Oishi R (2005) Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemo and Pharma 56(1):91\u201396. \n                    https:\/\/doi.org\/10.1007\/s00280-004-0924-9","journal-title":"Cancer Chemo and Pharma"},{"issue":"1","key":"4087_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000336772","volume":"74","author":"E Piovano","year":"2012","unstructured":"Piovano E, Pivetta E, Modaffari P, Martra F, Baima Poma C, Perotto S, Tripodi E, Zanfagnin V, Zola P, Ferrero A (2012) A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasm. Gyneco and Obstetric Invest 74(1):21\u201327. \n                    https:\/\/doi.org\/10.1159\/000336772","journal-title":"Gyneco and Obstetric Invest"},{"issue":"5-6","key":"4087_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1081\/CNV-120003535","volume":"20","author":"J Quock","year":"2002","unstructured":"Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D (2002) Premedication strategy for weekly paclitaxel. Cancer Investig 20(5-6):666\u2013672. \n                    https:\/\/doi.org\/10.1081\/CNV-120003535","journal-title":"Cancer Investig"},{"issue":"2-3","key":"4087_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000085618","volume":"51","author":"AS Braverman","year":"2005","unstructured":"Braverman AS, Rao S, Salvatti ME, Adamson B, McManus M, Pierre S (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51(2-3):116\u2013119. \n                    https:\/\/doi.org\/10.1159\/000085618","journal-title":"Chemotherapy"},{"key":"4087_CR17","unstructured":"GreenMCet al (2009) Rates of adverse events with low-dose dexamethasone (Dex) as premedication of weekly paclitaxel (Pac) utilized as adjuvant\/neoadjuvant therapy for operable breast cancer. In Program and Abstracts of the American Society of Clinical Oncology 2009 Breast Cancer Symposium:Abstract 307"},{"issue":"7","key":"4087_CR18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00520-014-2556-x","volume":"23","author":"MJ Berger","year":"2015","unstructured":"Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB (2015) Stop paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019\u20132024. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2556-x","journal-title":"Support Care Cancer"},{"issue":"9","key":"4087_CR19","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00520-011-1303-9","volume":"20","author":"MJ Berger","year":"2012","unstructured":"Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL (2012) Feasibility of stopping paclitaxel premedication after two dose in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 20(9):1991\u20131997. \n                    https:\/\/doi.org\/10.1007\/s00520-011-1303-9","journal-title":"Support Care Cancer"},{"key":"4087_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5372\/1905-7415.1004.500","volume":"4","author":"T Walailuk","year":"2016","unstructured":"Walailuk T et al (2016) Feasibility of withholding dexamethasone premedication in weekly paclitaxel administration and its associated adverse reactions. Asian Biomed 4:371\u2013377. \n                    https:\/\/doi.org\/10.5372\/1905-7415.1004.500","journal-title":"Asian Biomed"},{"issue":"10","key":"4087_CR21","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00520-009-0588-4","volume":"17","author":"LS Lal","year":"2009","unstructured":"Lal LS, Gerber DL, Lau J, Dana W (2009) Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer 17(10):1311\u20131315. \n                    https:\/\/doi.org\/10.1007\/s00520-009-0588-4","journal-title":"Support Care Cancer"},{"issue":"3","key":"4087_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000055093","volume":"24","author":"H Koppler","year":"2001","unstructured":"Koppler H et al (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24(3):283\u2013285. \n                    https:\/\/doi.org\/10.1159\/000055093","journal-title":"Onkologie"},{"issue":"3","key":"4087_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/gyno.2001.6546","volume":"84","author":"JS Kwon","year":"2002","unstructured":"Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K (2002) A comparison of two prophylactic regimen for hypersensitivity reaction to paclitaxel. Gynecol Oncol 84(3):420\u2013425. \n                    https:\/\/doi.org\/10.1006\/gyno.2001.6546","journal-title":"Gynecol Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4087-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T01:25:41Z","timestamp":1549934741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4087-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4087"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4087-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"1 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board of King Chulalongkorn Memorial Hospital and Chulalongkorn University approved the retrospective study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}